"When we started, RNA had been used in vaccines and in people and had failed. The clinical trials showed not good results and the pharmaceutical companies gave up on it," Weissman told ScienceBoard.net at the conclusion of the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.

Inflammation was at the heart of the RNA problem decades ago, according to Weissman, who said he and Kariko were able to figure out how to make it noninflammatory. Their nucleoside-modified mRNA technology and other vaccine-related improvements have been used by both Moderna and Pfizer-BioNTech in the development of their COVID-19 vaccines.

"I always have to laugh when people tell me 'I'm nervous about the vaccine, they invented it in 10 months' and that's as far from the truth as possible," Weissman said. "We were working on RNA for 25 years. We developed modified RNA over 15 years ago ... It wasn't brand new. It was just in the right place that when COVID hit this was a vaccine platform that biotech companies had experience with."

Watch the video below to learn more.

Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...

Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...

How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...

Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...

Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...

Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...

Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...